Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma.
2009-10-26
Article
volume 6, issue 5 pp 247-248.
| Related Files |
|---|
|
Redirect to publisher's version
(publisher's version.url.txt, 43 bytes) |
Repository contains one additional file which is not publicly available
A prospective subgroup analysis of two prospective, randomized, double-blind, placebo-controlled phase III clinical trials showed that the combination of lenalidomide plus dexamethasone is superior to dexamethasone alone in patients with relapsed or refractory multiple myeloma who had been previously treated with thalidomide; the implications for clinical practice are discussed.
Keywords
- human
- Humans
- Follow-Up Studies
- Prospective Studies
- Time Factors
- Treatment Outcome
- follow up
- recurrent disease
- randomized controlled trial
- Clinical Trials
- note
- Recurrence
- prospective study
- mortality
- antineoplastic agent
- time
- treatment outcome
- Survival Rate
- dose response
- double blind procedure
- Double-Blind Method
- drug derivative
- dexamethasone
- multiple myeloma
- thalidomide
- survival rate
- Chemotherapy
- phase 3 clinical trial
- Drug
- adjuvant chemotherapy
- Randomized Controlled Trials as Topic
- Dexamethasone
- lenalidomide
- Adjuvant
- Antineoplastic Combined Chemotherapy Protocols
- Dose-Response Relationship
- Multiple Myeloma
- Phase III as Topic
- Thalidomide
